CA1303500C - Vaccin contre la peritonite infectieuse chez les chats - Google Patents
Vaccin contre la peritonite infectieuse chez les chatsInfo
- Publication number
- CA1303500C CA1303500C CA 529116 CA529116A CA1303500C CA 1303500 C CA1303500 C CA 1303500C CA 529116 CA529116 CA 529116 CA 529116 A CA529116 A CA 529116A CA 1303500 C CA1303500 C CA 1303500C
- Authority
- CA
- Canada
- Prior art keywords
- virus
- fipv
- temperature
- passage
- feline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 30
- 208000005098 feline infectious peritonitis Diseases 0.000 title abstract description 31
- 241000711475 Feline infectious peritonitis virus Species 0.000 claims abstract description 52
- 241000282324 Felis Species 0.000 claims abstract description 29
- 241000700605 Viruses Species 0.000 claims description 94
- 238000004113 cell culture Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 9
- 231100001222 nononcogenic Toxicity 0.000 claims description 8
- 230000003053 immunization Effects 0.000 claims description 5
- 230000036760 body temperature Effects 0.000 claims description 4
- 241000725579 Feline coronavirus Species 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 abstract description 24
- 230000036039 immunity Effects 0.000 abstract description 2
- 241000282326 Felis catus Species 0.000 description 77
- 238000002255 vaccination Methods 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 17
- 206010037660 Pyrexia Diseases 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000003472 neutralizing effect Effects 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 208000037921 secondary disease Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 208000030208 low-grade fever Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000002020 sage Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 241001163743 Perlodes Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- CJRJTCMSQLEPFQ-UHFFFAOYSA-N 6-cat Chemical compound ClC1=CC=C2CC(N)CCC2=C1 CJRJTCMSQLEPFQ-UHFFFAOYSA-N 0.000 description 1
- NALREUIWICQLPS-UHFFFAOYSA-N 7-imino-n,n-dimethylphenothiazin-3-amine;hydrochloride Chemical compound [Cl-].C1=C(N)C=C2SC3=CC(=[N+](C)C)C=CC3=NC2=C1 NALREUIWICQLPS-UHFFFAOYSA-N 0.000 description 1
- 101100112372 Acinetobacter baylyi (strain ATCC 33305 / BD413 / ADP1) catM gene Proteins 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100120137 Caenorhabditis elegans fip-3 gene Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241001315286 Damon Species 0.000 description 1
- 101100342039 Halobacterium salinarum (strain ATCC 29341 / DSM 671 / R1) kdpQ gene Proteins 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101100536883 Legionella pneumophila subsp. pneumophila (strain Philadelphia 1 / ATCC 33152 / DSM 7513) thi5 gene Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 101100240664 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nmt1 gene Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 101150053553 catR gene Proteins 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- SICOMVQWPQHCBY-UHFFFAOYSA-N propan-2-one;1,2-xylene Chemical group CC(C)=O.CC1=CC=CC=C1C SICOMVQWPQHCBY-UHFFFAOYSA-N 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82663886A | 1986-02-06 | 1986-02-06 | |
| US826,638 | 1986-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1303500C true CA1303500C (fr) | 1992-06-16 |
Family
ID=25247142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 529116 Expired - Lifetime CA1303500C (fr) | 1986-02-06 | 1987-02-05 | Vaccin contre la peritonite infectieuse chez les chats |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0261168A1 (fr) |
| JP (1) | JPS63502828A (fr) |
| AU (1) | AU604682B2 (fr) |
| CA (1) | CA1303500C (fr) |
| WO (1) | WO1987004624A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL87911A0 (en) * | 1987-10-01 | 1989-03-31 | Norden Lab Inc | Vaccine for protection of cats against feline infectious peritonitis |
| US5667785A (en) * | 1987-10-01 | 1997-09-16 | Pfizer Inc. | Vaccine for protection of cats against feline infectious peritonitis |
| CA2005291C (fr) * | 1988-12-30 | 1999-01-26 | Beverly Dale | Instruments de diagnostic du virus de la peritonite infectieuse des felins |
| NZ240558A (en) | 1990-11-14 | 1994-11-25 | Smithkline Beecham Corp | Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease |
| US6033845A (en) * | 1996-12-18 | 2000-03-07 | Engene Biotechnologies Inc | Specific diagnostic for feline infectious peritonitis antibodies |
| US6106841A (en) * | 1998-02-04 | 2000-08-22 | Heska Corporation | Delivery method for recombinant raccoon poxvirus |
| CN116042538B (zh) * | 2022-11-24 | 2024-05-07 | 华中农业大学 | 一株猫冠状病毒及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4021302A (en) * | 1966-02-18 | 1977-05-03 | Burroughs Wellcome & Co., Inc. | Cell cultures |
| US4195130A (en) * | 1978-04-20 | 1980-03-25 | Cornell Research Foundation, Inc. | Propagation of feline infectious peritonitis virus in tissue cultures |
| ZA796477B (en) * | 1978-11-30 | 1981-07-29 | Wellcome Found | Feline infectious peritonitis vaccine |
| ES8107025A1 (es) * | 1978-11-30 | 1980-12-16 | Wellcome Found | Un metodo de preparar una vacuna que contiene una cepa ate- nuada de virus de peritonitis infecciosa felina. |
| US4303644A (en) * | 1979-10-16 | 1981-12-01 | Norden Laboratories, Inc. | Feline infectious peritonitis virus vaccines |
-
1987
- 1987-02-05 AU AU70372/87A patent/AU604682B2/en not_active Ceased
- 1987-02-05 WO PCT/US1987/000216 patent/WO1987004624A1/fr not_active Application Discontinuation
- 1987-02-05 CA CA 529116 patent/CA1303500C/fr not_active Expired - Lifetime
- 1987-02-05 JP JP62501403A patent/JPS63502828A/ja active Pending
- 1987-02-05 EP EP87901809A patent/EP0261168A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP0261168A1 (fr) | 1988-03-30 |
| AU604682B2 (en) | 1991-01-03 |
| AU7037287A (en) | 1987-08-25 |
| WO1987004624A1 (fr) | 1987-08-13 |
| JPS63502828A (ja) | 1988-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Snyder et al. | Group and strain-specific neutralization sites of infectious bursal disease virus defined with monoclonal antibodies | |
| Prinzie et al. | Experimental live attenuated rubella virus vaccine: clinical evaluation of Cendehill strain | |
| CA1045546A (fr) | Vaccin a cytomegalovirus fortement attenue | |
| US3944469A (en) | Feline calicivirus vaccine and production thereof | |
| US3937812A (en) | Feline calicivirus vaccine and production thereof | |
| CA1303500C (fr) | Vaccin contre la peritonite infectieuse chez les chats | |
| JPS6257307B2 (fr) | ||
| Wu et al. | Antigenic and immunogenic characterization of infectious bronchitis virus strains isolated in China between 1986 and 1995 | |
| US5460815A (en) | Feline infectious peritonitis vaccine and method of preparation | |
| US7029682B2 (en) | Inactivated vaccine against feline calicivirosis | |
| US5972350A (en) | Feline vaccines containing Chlamydia psittaci and method for making the same | |
| EP0310362B1 (fr) | Vaccin pour la protection des chats contre la péritonite infectieuse féline | |
| US5043157A (en) | Feline infectious peritonitis vaccine and method of preparation | |
| CA1058074A (fr) | Vaccin contre la rhinotracheite des felins et mode de production | |
| US4287178A (en) | Feline rhinotracheitis vaccine and production and use thereof | |
| CA2378802C (fr) | Vaccin inactive contre la calicivirose feline | |
| US5670156A (en) | Feline infectious peritonitis vaccine and method of preparation | |
| ZA200402352B (en) | Chicken anemia virus vaccine from cell line. | |
| Bayyari et al. | Antigenic characterization of an Arkansas isolate of infectious bursal disease virus | |
| US5667785A (en) | Vaccine for protection of cats against feline infectious peritonitis | |
| KR100556275B1 (ko) | 클라미디아시타시를함유하는고양이백신및그의제조방법 | |
| US20020146425A1 (en) | Feline vaccines containing chlamydia psittaci and method for making the same | |
| Bayyari | The cloning, attenuation, and antigenic characterization of an Arkansas isolate of infectious bursal disease virus | |
| Vera | Expression and immunogenicity of the S1 subunit of the spike glycoprotein of turkey coronavirus in an avian hepatoma cell line | |
| ZA200201232B (en) | Inactivated vaccine against feline calicivirus disease. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |